




PHARMACEUTICAL 2023

Aeglea BioTherapeutics Inc.
Rank 296 of 446





PHARMACEUTICAL 2023

Aeglea BioTherapeutics Inc.
Rank 296 of 446



The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is 5.9%, being 37% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	62,258
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,656
Liabilities, Non-Current	4,004
Other Assets	5,666
Other Compr. Net Income	-28
Other Expenses	-136
Other Liabilities	2,179
Other Net Income	830
Other Revenues	2,329
Property and Equipment	3,220
Research and Development	58,579
Selling, General and Administrative Expense	28,531

Output Variable	Value in 1000 USD
Assets	71,144
Liabilities	20,839
Expenses	86,974
Revenues	2,329
Stockholders Equity	50,305
Net Income	-83,815
Comprehensive Net Income	-83,829
Economic Capital Ratio	5.9%